Home News Covid-19

Singapore eDevelopment shares surged as high as 79% following news of its success against Covid-19 with its biotechnologies

Felicia Tan
Felicia Tan6/24/2020 05:57 PM GMT+08  • 1 min read
Singapore eDevelopment shares surged as high as 79% following news of its success against Covid-19 with its biotechnologies
Shares in Singapore eDevelopment (SeD) surged as high as 79% to 10 cents following its announcement of its in-vitro success against Covid-19 with its biotechnologies.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

SINGAPORE (June 24): Shares in Singapore eDevelopment (SeD) surged as high as 79% to 10 cents following its announcement of its in-vitro success against Covid-19 with its biotechnologies.

Earlier today, SeD’s wholly-owned subsidiary Impact Biomedical said it has successfully proved in-vitro success of Equivir, an over-the-counter (OTC) medication, and 3F Biofragrance, a surface disinfectant, against Covid-19.

Currently, no known COVID-19 vaccines or preventive medication have been developed.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.